Autolus Reports Promising CAR-T Results for Severe Lupus and Pediatric Leukemia at ASH 2025
核心洞察
Autolus presented updated data from the CARLYSLE trial showing obe-cel achieved 83% DORIS response rates in severe refractory systemic lupus erythematosus patients with deep B-cell depletion and no high-grade toxicities.
The CATULUS pediatric trial demonstrated a 95.5% overall response rate in high-risk relapsed/refractory B-ALL patients, with low rates of severe cytokine release syndrome and neurotoxicity.
Post-hoc analyses from the FELIX study identified CAR-T persistence at three months and central memory cell composition as potential predictors of long-term outcomes in adult B-ALL patients.
Autolus Therapeutics presented compelling clinical data at the American Society of Hematology (ASH) Annual Meeting 2025, showcasing the versatility of its CD19 (搜索)-directed CAR-T therapy obecabtagene autoleucel (obe-cel) across both autoimmune and oncology indications. The presentations highlighted significant therapeutic potential in severe refractory systemic lupus erythematosus and pediatric acute lymphoblastic leukemia.
Breakthrough Results in Severe Lupus
The Phase 1 CARLYSLE trial demonstrated remarkable efficacy in patients with severe refractory systemic lupus erythematosus (srSLE), a population with extremely limited treatment options. Nine patients received obe-cel infusions, with six at the 50 million cell dose and three at the 100 million cell dose.
At the 50 million cell dose level, 83% of patients achieved DORIS (Definition of Remission in SLE) responses with a median onset of 5.1 months. Three patients (50%) achieved complete renal response (CRR), and all non-renal disease manifestations resolved by month four. The median follow-up reached 12 months, with no evidence of new disease activity.
"Patients with srSLE have limited remaining treatment options and represent a difficult to treat population with a critical unmet need," said Dr. Matthias Will, Chief Development Officer of Autolus. "Data reported from the CARLYSLE trial show an encouraging high rate of DORIS responses and a deep reset in the B cell compartment induced by obe-cel."
The safety profile proved favorable, with no dose-limiting toxicities or immune effector cell-associated neurotoxicity syndrome (ICANS) observed at the 50 million dose. Grade 1 cytokine release syndrome occurred in three patients at each dose level. All patients demonstrated deep B-cell depletion following infusion, suggesting an immune system reset.
Pediatric Leukemia Success
The CATULUS Phase 1 trial enrolled high-risk pediatric patients under 18 years with relapsed/refractory B-ALL, including those with primary refractory disease, high-risk first relapse, or second or later relapse. The overall response rate reached 95.5% (21 patients), with 90.9% achieving complete response.
Twenty patients remained in ongoing remission at data cutoff with a median follow-up of 8.8 months. The safety profile mirrored adult experience, with low rates of high-grade CRS and ICANS (both 8.7%).
"We were pleased to share the first data from the Phase 1 CATULUS trial showing obe-cel can produce high remission rates in this pediatric patient population, including in patients with high-risk relapse and patients with primary CNS relapse," Dr. Will noted.
Predictive Biomarkers Identified
Post-hoc analyses from the registrational FELIX study in adult relapsed/refractory B-ALL revealed potential predictors of long-term outcomes. Among 79 patients in ongoing remission at three months post-infusion, 75.9% maintained CAR-T cell persistence while 24.1% showed loss of persistence.
Patients with ongoing CAR-T persistence at three months demonstrated longer event-free survival and overall survival compared to those with loss of persistence. Additionally, a higher percentage of central memory T cells (Tcm) in the drug product independently predicted positive clinical outcomes, including overall survival.
Real-World Validation
Independent real-world data from the ROCCA consortium during obe-cel's US commercial launch corroborated the clinical trial experience. The data showed high response rates and low levels of high-grade CRS and ICANS, consistent with the FELIX study results.
Regulatory Progress
Based on the positive CARLYSLE results, Autolus has initiated the LUMINA trial, a Phase 2 study in lupus nephritis with registrational intent. The company has aligned with the FDA on the Phase 2 trial design and potential registrational pathway to approval, with 50 million cells selected as the recommended Phase 2 dose.
"Obe-cel successfully underwent the regulatory approval process with the FDA, EMA and MHRA in adult r/r B-ALL and launched commercially in the US and UK in 2025," said Dr. Christian Itin, Autolus Chief Executive Officer. "Building on this strong foundation of clinical data, and demonstrated commercial and manufacturing capabilities, we believe Autolus is well positioned for a successful and efficient path into the autoimmune setting."
The presentations underscore obe-cel's potential to address significant unmet medical needs across multiple therapeutic areas, with its differentiated safety profile and manufacturing capabilities positioning Autolus for continued expansion into new indications.